Periotherapia Co., Ltd. announced that it has received ¥390 million in a equity round of funding co-led by returning investors Mitsubishi UFJ Life Science II, Limited Partnership, a fund managed by Mitsubishi UFJ Capital Co., Ltd., and OUVC Fund 1 Limited Partnership, a fund managed by Osaka University Venture Capital Co., Ltd. on June 27, 2024. The transaction included participation from new investors Techno Science, Inc., Eisai Co., Ltd. The company raised money through a third-party allotment of new shares. The company has raised a total money of ¥1.57 billion in funding till date.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6,592 JPY | -0.56% | +3.63% | -6.52% |
06-28 | Eisai and Biogen launch Alzheimer's drug Leqembi in China | RE |
06-28 | Eisai Co., Ltd. and Biogen Inc. Announces Launch of Leqembi in China | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.52% | 11.74B | |
+55.32% | 815B | |
+44.05% | 641B | |
-6.75% | 352B | |
+13.56% | 314B | |
+10.68% | 303B | |
+16.57% | 242B | |
+13.31% | 218B | |
+8.48% | 168B | |
-2.81% | 159B |
- Stock Market
- Equities
- 4523 Stock
- News Eisai Co., Ltd.
- Periotherapia Co., Ltd. announced that it has received ¥390 million in funding from Mitsubishi UFJ Capital Co., Ltd., Eisai Co., Ltd., Techno Science, Inc., Chishima Real Estate Co., Ltd., Osaka University Venture Capital Co., Ltd.